Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

MYLAN NV (MYL)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Mylan : Announces Voluntary Delisting from the Tel Aviv Stock Exchange (TASE)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:46pm CEST

HERTFORDSHIRE, England and PITTSBURGH, Nov. 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it is voluntarily delisting the company's ordinary shares from trading on the Tel Aviv Stock Exchange (TASE). Under Israeli law, the delisting of Mylan's ordinary shares from the TASE will become effective in three months, on Feb. 12, 2018.

When Mylan first listed its shares on the TASE in November 2015, in connection with its attempt to acquire Perrigo, it committed to maintaining the listing for at least one year. Mylan has been listed on the TASE for more than two years.

Mylan's Chairman of the Board Robert J. Coury noted: "Over the last two years, we have learned that many of our Israeli institutional shareholders actually hold their shares in Mylan on the NASDAQ. Further, Mylan's holding on the TASE represents less than 3.5% of our total shareholdings and the average trading volume on the TASE is less than 3.5% of our global trading volume. Given these factors and the fact that the TASE's trading hours and days are different from other markets, our board of directors decided at this time that it would not be in Mylan's best interests to continue our listing on the TASE. That said, we do appreciate the ties we have forged with the Israeli institutional market."

Coury continued, "More importantly, over the last two years, I have had the privilege of becoming acquainted with the dynamic Israeli business environment and the strong work ethic of its people. As a result, we remain committed to considering future investments and other business development opportunities in Israel."

Mylan's shares will continue to be listed on the NASDAQ, and all of its ordinary shares now traded on the TASE may be transferred to the NASDAQ.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/mylan-announces-voluntary-delisting-from-the-tel-aviv-stock-exchange-tase-300553811.html

SOURCE Mylan N.V.


© PRNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MYLAN NV
10/12MYLAN : Gets Favorable Appeals Court Ruling in Patent Dispute Over Teva's Copaxo..
DJ
10/12MYLAN : Prevails in Copaxone® 40mg/mL Litigation Against Teva in U.S. Appellate ..
PR
10/12MYLAN : Launches Vivarin™ Caffeine Gum to Provide a Boost of Caffeine Wher..
PU
10/11MYLAN : Theravance Biopharma and Mylan Report Positive New Data from Multiple St..
PU
10/08PIERRE FABRE : sources
RE
10/08MYLAN : Theravance Biopharma and Mylan to Present New Data from Studies of YUPEL..
PR
09/27FDA OKs Lower Dose of EpiPen Alternative Drug That Adamis Licensed to Sandoz
DJ
09/26MYLAN : Championing Women’s Health in India
PU
09/24MYLAN : Extends Commitment to Fight HIV/AIDS by Partnering with Atomo Diagnostic..
PR
09/21MYLAN : and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegf..
PR
More news
News from SeekingAlpha
10/13STOCKS TO WATCH : Was That A Speed Bump? 
10/12Mylan prevails in patent challenge to Teva's Copaxone 
10/12Merck bails on Lantus biosimilar 
10/10Greenlight Capital's (David Einhorn) Q3 2018 Letter 
10/09Agile Therapeutics up 62% on development path for Twirla